Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Description

The purpose of this "first-in-human" study of PDR001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of PDR001 administered i.v. as a single agent to adult patients with solid tumors. By blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, PDR001 inhibits the PD-1 immune checkpoint, resulting in activation of an antitumor immune response by activating effector T-cells and inhibiting regulatory T-cells. This study has been designed as a phase I/II, multi-center, open-label study starting with a phase I dose escalation part followed by a phase II part. PDR001 will be administered every 2 weeks until patient experiences unacceptable toxicity, progressive disease per immune related Response Criteria (irRC) and/or treatment is discontinued at the discretion of the investigator or the patient.

Study Start Date

April 2015

Estimated Completion Date

April 2018

Interventions

  • Biological: PDR001

Specialties

  • Oncology: Dermatologic Oncology
  • Pharmacy: Chemotherapy/Oncology
  • Dermatology: Dermatologic Oncology

MeSH Terms

  • Melanoma
  • PDR001

Study ID

Novartis -- CPDR001X2101

Status

Unknown

Trial ID

NCT02404441

Study Type

Interventional

Trial Phase

Phase 1/Phase 2

Enrollment Quota

180

Sponsor

Novartis

Inclusion Criteria

  • Written informed consent must be obtained prior to any screening procedures
  • Phase I part: Patients with advanced/metastatic solid tumors, with measurable or non-measurable disease as determined by RECIST version 1.1 (refer to Appendix 1), who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists.
  • Phase II part: Patients with advanced/metastatic solid tumors, with at least one measurable lesion as determined by RECIST version 1.1, who have received standard therapy or are intolerant of standard therapy, have progressed following their last prior therapy, and fit into one of the following groups:
  • Group 1: NSCLC (no selection for PD-L1)
  • Group 2: Melanoma (no selection for PD-L1)
  • Group 3: Gastric cancer and esophageal adenocarcinoma (including tumors involving the gastro-esophageal junction) positive for PD-L1 expression.
  • Group 4: CRC that is MSI-High (MSI-H), positive for PD-L1 expression
  • Group 5: Anal cancer positive for PD-L1 expression
  • ECOG Performance Status ? 2.
  • Patients must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy. Patient must be willing to undergo a new tumor biopsy at baseline, and during therapy on this study.

Exclusion Criteria

  • History of severe hypersensitivity reactions to other mAbs
  • Active autoimmune disease or a documented history of autoimmune disease, except vitiligo or resolved childhood asthma/atopy.
  • Active infection requiring systemic antibiotic therapy.
  • Known history of HIV infection.
  • Active HBV or HCV infection.
  • Systemic anti-cancer therapy within 2 weeks of the first dose of study treatment. For cytotoxic agents that have major delayed toxicity, e.g. mitomycin C and nitrosoureas, 4 weeks washout period.
  • Prior PD-1
  • or PD-L1-directed therapy.
  • Patients receiving treatment with systemic steroid therapy, other than replacement-dose steroids in the setting of adrenal insufficiency. Topical, inhaled, nasal and ophthalmic steroids are not prohibited.
  • Patients receiving systemic treatment with any immunosuppressive medication.
  • Use of any vaccines against infectious diseases (e.g. influenza, varicella, pneumococcus) within 4 weeks of initiation of study treatment.
  • Presence of ? CTCAE grade 2 toxicity (except alopecia, peripheral neuropathy and ototoxicity, which are excluded if ? CTCAE grade 3) due to prior cancer therapy Other protocol defined Inclusion/Exclusion may apply.

Gender

Both

Ages

18 Years and older

Accepts Healthy Volunteers

No

Study Locations and Contact Information (3)

Study Location Distance Name Phone Email
Massachusetts General Hospital - Boston, Massachusetts 2.8 miles Carrie Quadrino 617-724-8228 cquadrino@partners.org
Sarah Cannon Research Institute SCRI RC - Nashville, Tennessee 942.8 miles Leah Flynn 615-329-7432 leah.flynn@scresearch.net
Oregon Health Science University SC10 - Portland, Oregon 2,538.3 miles Cassie Thompkins 503-418-9324 tompkica@ohsu.edu

ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.